Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Buy” from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned a consensus recommendation of “Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $6.63.

TSHA has been the topic of a number of recent research reports. JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th.

Taysha Gene Therapies Stock Up 7.1 %

Taysha Gene Therapies stock opened at $2.58 on Wednesday. The firm has a market cap of $529.04 million, a price-to-earnings ratio of 4.10 and a beta of 0.90. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $4.32. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $1.80.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. Equities analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TSHA. Charles Schwab Investment Management Inc. boosted its holdings in shares of Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company’s stock valued at $820,000 after purchasing an additional 11,390 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Taysha Gene Therapies by 23.7% in the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares in the last quarter. Barclays PLC boosted its stake in Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after buying an additional 193,046 shares during the last quarter. LPL Financial LLC purchased a new position in Taysha Gene Therapies during the 4th quarter valued at approximately $104,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $8,650,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.